3-(3,4,5-trimethoxybenzoyl)-6-methoxy-7-isopropoxybenzo[b]furan | 905752-35-4

• 分子结构分类: 有机化合物 - 有机氧化合物
• 英文名称: 3-(3,4,5-trimethoxybenzoyl)-6-methoxy-7-isopropoxybenzo[b]furan
• 英文别名: 3-(3,4,5-trimethoxybenzoyl)-6-methoxy-7-isopropoxy-benzofuran；3-(3,4,5-Trimethoxybenzoyl)-6-methoxy-7-isopropoxybenzofuran；(6-methoxy-7-propan-2-yloxy-1-benzofuran-3-yl)-(3,4,5-trimethoxyphenyl)methanone
• CAS: 905752-35-4
• 化学式: C₂₂H₂₄O₇
• 分子量: 400.428
• InChiKey: NZPYLABNHVVSQI-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.3
• 重原子数：
  29
• 可旋转键数：
  8
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.32
• 拓扑面积：
  76.4
• 氢给体数：
  0
• 氢受体数：
  7

反应信息

• 作为反应物：
  描述：

  3-(3,4,5-trimethoxybenzoyl)-6-methoxy-7-isopropoxybenzo[b]furan 在 aluminum (III) chloride 、 水 、 氯化铵 作用下， 以 二氯甲烷 为溶剂， 反应 0.33h， 以86%的产率得到7-hydroxy-6-methoxy-3-(3,4,5-trimethoxybenzoyl)benzo[b]furan
  参考文献：
  名称：

  WO2006/84338

  摘要：

  公开号：
• 作为产物：
  描述：

  2-isopropoxy-3-methoxy-6-iodophenol 在 四丁基氟化铵 、 palladium diacetate 、 sodium carbonate 作用下， 以 四氢呋喃 、 N,N-二甲基甲酰胺 为溶剂， 反应 0.33h， 生成 3-(3,4,5-trimethoxybenzoyl)-6-methoxy-7-isopropoxybenzo[b]furan
  参考文献：
  名称：

  Discovery of 7-Hydroxy-6-methoxy-2-methyl-3-(3,4,5-trimethoxybenzoyl)benzo[b]furan (BNC105), a Tubulin Polymerization Inhibitor with Potent Antiproliferative and Tumor Vascular Disrupting Properties

  摘要：

  A structure activity relationship (SAR) guided design of novel tubulin polymerization inhibitors has resulted in a series of benzo[b]furans with exceptional potency toward cancer cells and activated endothelial cells. The potency of early lead compounds has been substantially improved through the synergistic effect of introducing a conformational bias and additional hydrogen bond donor to the pharmacophore. Screening of a focused library of potent tubulin polymerization inhibitors for selectivity against cancer cells and activated endothelial cells over quiescent endothelial cells has afforded 7-hydroxy-6-methoxy-2-methyl-3-(3,4,5-trimethoxybenzoyl)benzo-[b]furan (BNC105, 8) as a potent and selective antiproliferative. Because of poor solubility, 8 is administered as its disodium phosphate ester prodrug 9 (BNC105P), which is rapidly cleaved in vivo to return the active 8. 9 exhibits both superior vascular disrupting and tumor growth inhibitory properties compared with the benchmark agent combretastatin A-4 disodium phosphate 5 (CA4P).

  DOI：

  10.1021/jm200454y

文献信息

• SUBSTITUTED BENZOFURANS, BENZOTHIOPHENES, BENZOSELENOPHENES AND INDOLES AND THEIR USE AS TUBULIN POLYMERISATION INHIBITORS
  申请人：Chaplin Jason Hugh

  公开号：US20100004208A1

  公开（公告）日：2010-01-07

  The present invention relates generally to substituted benzofurans, benzothiophenes, and indoles and their use as tubulin polymerisation inhibitors.

  本发明涉及取代苯并呋喃、苯并噻吩和吲哚，以及它们作为微管聚合抑制剂的用途。
• Tubulin polymerisation inhibitors
  申请人：Biononics Limited

  公开号：US08278290B2

  公开（公告）日：2012-10-02

  The present invention relates to compounds of general formula (I) as tublin polymerization inhibitors and methods for preparing such compounds.

  本发明涉及一般式（I）化合物作为微管聚合抑制剂和制备这些化合物的方法。
• Substituted benzofurans, benzothiophenes, benzoselenophenes and indoles and their use as tubulin polymerisation inhibitors
  申请人：Bionomics Limited

  公开号：US08198466B2

  公开（公告）日：2012-06-12

  The present invention relates generally to substituted benzofurans, benzothiophenes, and indoles and their use as tubulin polymerization inhibitors.

  本发明涉及取代苯并呋喃、苯并噻吩和吲哚类化合物，并将其用作微管聚合抑制剂。
• NOVEL TUBULIN POLYMERISATION INHIBITORS
  申请人：Chaplin Jason Hugh

  公开号：US20120309768A1

  公开（公告）日：2012-12-06

  The present invention relates to compounds of general formula (I) as tublin polymerisation inhibitors and methods for preparing such compounds.

  本发明涉及一般式（I）的化合物，作为微管聚合抑制剂以及制备这些化合物的方法。
• Substituted Benzofurans, Benzothiophenes, Benzoselenophenes and Indoles And Their Use as Tubulin Polymerisation Inhibitors
  申请人：Bionomics Limited

  公开号：EP2460793A1

  公开（公告）日：2012-06-06

  The present invention relates generally to substituted benzofurans, benzothiophenes, and indoles and their use as tubulin polymerisation inhibitors. wherein; X represents O, S, SO, SO2, Se, SeO, SeO2 or NR where R is selected from H, O, optionally substituted acyl, optionally substituted alkenyl, optionally substituted alkyl, optionally substituted aryl, optionally substituted cycloalkenyl, optionally substituted cycloalkyl, optionally substituted heteroaryl, optionally substituted heterocyclyl, and optionally substituted sulfonyl; R1C represents C1-3 alkoxy, C1-3 alkylthio, C1-3 alkylamino, or C1-3 dialkylamino; R1D represents hydroxy or amino; L represents C=O, O, S, SO, SO2, Se, SeO, SeO2, C=NZ', or NR' where Z' is H, optionally substituted alkyl, optionally substituted aryl or optionally substituted amino; and where R' is selected from H, O, optionally substituted acyl, optionally substituted alkenyl, optionally substituted alkyl, optionally substituted aryl, optionally substituted cycloalkenyl, optionally substituted cycloalkyl, optionally substituted heteroaryl, optionally substituted heterocyclyl, or optionally substituted sulfonyl; The other variables are as defined in the claims.

  本发明一般涉及取代的苯并呋喃、苯并噻吩和吲哚，以及它们作为微管蛋白聚合抑制剂的用途。 其中 X代表O、S、SO、SO2、Se、SeO、SeO2或NR，其中R选自H、O、任选取代的酰基、任选取代的烯基、任选取代的烷基、任选取代的芳基、任选取代的环烯基、任选取代的环烷基、任选取代的杂芳基、任选取代的杂环基和任选取代的磺酰基； R1C 代表 C1-3 烷氧基、C1-3 烷硫基、C1-3 烷氨基或 C1-3 二烷基氨基； R1D 代表羟基或氨基； L 代表 C=O、O、S、SO、SO2、Se、SeO、SeO2、C=NZ'或 NR'，其中 Z'是 H、任选取代的烷基、任选取代的芳基或任选取代的氨基；R'选自 H、O、任选取代的酰基、任选取代的烯基、任选取代的烷基、任选取代的芳基、任选取代的环烯基、任选取代的环烷基、任选取代的杂芳基、任选取代的杂环基或任选取代的磺酰基； 其他变量如权利要求中所定义。